Last reviewed · How we verify
NCT04655794
Clinical Analysis of Safety in Latent Tuberculosis Infection Prophylaxis Treatment
trial testing 3HP in Adverse Reaction to Drug in 500 participants. Status unknown.
20 November 2020
Quick facts
| Lead sponsor | Chang Gung Memorial Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 19 April 2018 |
| Primary completion | 20 November 2020 |
| Estimated completion | 12 February 2021 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- 3HP — full drug profile →
Conditions studied
- Adverse Reaction to Drug — all drugs for Adverse Reaction to Drug →
- 3HP — all drugs for 3HP →
Sponsor
Chang Gung Memorial Hospital
Who can join
Adults 20 to 100, any sex, with Adverse Reaction to Drug or 3HP. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The treatment of latent TB with 3HP is an important issue for the prevention of active TB. However, significant proportion of subjects receiving 3HP had adverse reaction. The main purpose of this observation study is to identify subjects who have higher risk to develop adverse reaction. Clinical characteristics and biomarker will be used to predict adverse reaction.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Plasma Concentrations of sTREM-1 as Markers for Systemic Adverse Reactions in Subjects Treated With Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
Wang TY, Feng JY, Shu CC, Lee SS, et al · · 2022 · cited 3× · PMID 35308376 · DOI 10.3389/fmicb.2022.821066
Verify or expand the search:
- PubMed search for NCT04655794
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 3HP
Trials testing the same drug.
- NCT05122767 — Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (D · Phase 1, PHASE2 · active not recruiting
- NCT02689089 — Taima TB: 3HP Study · Phase 4 · completed
Other Chang Gung Memorial Hospital trials
Trials by the same sponsor.
- NCT07419789 — Precision Care for Older Persons · NA · not yet recruiting
- NCT07248345 — Virtual Reality Intervention for Family Caregivers of Persons Living With Dementia · NA · not yet recruiting
- NCT07036978 — Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer · not yet recruiting
- NCT07489833 — Metabolomic Pathways and Traditional Chinese Medicine Body Constitution in Cancer-related Fatigue · not yet recruiting
- NCT07496528 — The ACURE Trial: Acupuncture for Colorectal Recovery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04655794 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chang Gung Memorial Hospital
- Last refreshed: 7 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04655794.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing